诃子抗类风湿性关节炎的药效物质基础及药理作用研究

被引：19

作者：

刘芳 ^{[1
]}

张璞 ^{[2
]}

赵鸿燕 ^{[1
]}

谢永红 ^{[1
]}

刘松青 ^{[1
,3
]}

机构：

[1] 第三军医大学第一附属医院药剂科

[2] 重庆市食品药品检验检测研究院

[3] 重庆医科大学附属第三医院药剂科

来源：

中国药房 | 2017年 / 28卷 / 25期

关键词：

诃子; 类风湿性关节炎; 治疗现状; 药效物质基础; 药理作用;

D O I：

暂无

中图分类号：

R285.5 [中药实验药理];

学科分类号：

100806 [中药药理学];

摘要：

目的:为进一步研究诃子抗类风湿性关节炎(RA)的药效物质基础及药理作用机制提供参考。方法:以"诃子""类风湿性关节炎""药理""Rheumatoid arthritis""Terminalia chebula"等为关键词,组合查询自建库起至2017年5月1日在PubMed、Web of Science、Embase、中国知网、维普等数据库中的相关文献,从RA的发病机制及病理过程、西药和中药治疗RA的现状、诃子抗RA的药效物质基础和药理作用等方面进行综述。结果与结论:共检索到相关文献261篇,其中有效文献39篇。RA发病机制复杂,目前尚无特效治愈药。化学药与生物制剂的治疗目标为使疾病缓解或处于低疾病活动状态;中药则以祛风除湿、通络止痛为治疗原则。酚酸类化合物和萜类化合物是诃子发挥抗RA的主要药效物质基础。诃子具有镇痛抗炎、调节免疫、诱导细胞凋亡和保护软骨等多方面的抗RA药理作用,既可改善RA症状也可控制RA病程发展。目前关于诃子抗RA的药效物质还缺乏系统性基础研究,主要集中于酚酸类成分,且大多属于药效学的观察研究,缺乏较为深入的机制探讨。

引用

页码：3575 / 3578

页数：4

共 26 条

[1]

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis [J].

Singh, Jasvinder A. ;

Saag, Kenneth G. ;

Bridges, S. Louis, Jr. ;

Akl, Elie A. ;

Bannuru, Raveendhara R. ;

Sullivan, Matthew C. ;

Vaysbrot, Elizaveta ;

McNaughton, Christine ;

Osani, Mikala ;

Shmerling, Robert H. ;

Curtis, Jeffrey R. ;

Furst, Daniel E. ;

Parks, Deborah ;

Kavanaugh, Arthur ;

O'Dell, James ;

King, Charles ;

Leong, Amye ;

Matteson, Eric L. ;

Schousboe, John T. ;

Drevlow, Barbara ;

Ginsberg, Seth ;

Grober, James ;

St Clair, E. William ;

Tindall, Elizabeth ;

Miller, Amy S. ;

McAlindon, Timothy .

ARTHRITIS & RHEUMATOLOGY, 2016, 68 (01) :1-26

[2]

The role of cytokines in the pathogenesis of rheumatoid arthritis – Practical and potential application of cytokines as biomarkers and targets of personalized therapy.[J].Edyta Brzustewicz;Ewa Bryl.Cytokine.2015, 2

[3]

OCCURRENCE OF TREATMENT INTERRUPTION DURING THERAPY WITH BIOLOGICAL AGENTS IN PATIENTS WITH PREVIOUS ANTI-TNF FAILURE IN RHEUMATOID ARTHRITIS [J].

Piazza, T. ;

Tonin, F. S. ;

Steinbach, L. M. ;

Wieus, A. ;

Pontarolo, R. .

VALUE IN HEALTH, 2015, 18 (07) :A874-A874

[4]

BIOLOGICAL AGENTS FOR PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD FAILED TREATMENT WITH METHOTREXATE IN THE SPANISH CLINICAL SETTING: A COST-EFFECTIVENESS ANALYSIS [J].

Sanchez, R. ;

Restovic, G. ;

Planellas, L. .

VALUE IN HEALTH, 2015, 18 (07) :A645-A646

[5]

Chebulagic acid inhibits the LPS‑induced expression of TNF‑α and IL‑1βin endothelial cells by suppressing MAPK activation.[J].Yueying Liu;Luer Bao;Liying Xuan;Baohua Song;Lin Lin;Hao Han.Experimental and Therapeutic Medicine.2015, 1

[6]

Global; regional; and national incidence; prevalence; and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries; 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.[J].Theo Vos;Ryan M Barber;Brad Bell;Amelia Bertozzi-Villa;Stan Biryukov;Ian Bolliger;Fiona Charlson;Adrian Davis;Louisa Degenhardt;Daniel Dicker;Leilei Duan;Holly Erskine;Valery L Feigin;Alize J Ferrari;Christina Fitzmaurice;Thomas Fleming;Nicholas Graetz;Caterina Guino

[7]

The role of the synovial fibroblast in rheumatoid arthritis pathogenesis [J].

Turner, Jason D. ;

Filer, Andrew .

CURRENT OPINION IN RHEUMATOLOGY, 2015, 27 (02) :175-182

[8]

Matrix metalloproteinase inhibitors: a patent review (2011 – 2013).[J].Nian-Guang Li;Yu-Ping Tang;Jin-Ao Duan;Zhi-Hao Shi.Expert Opinion on Therapeutic Patents.2014, 9

[9]

The anti-inflammatory effect of triphala in arthritic-induced rats.[J].Sowmiya Kalaiselvan;Mahaboob Khan Rasool.Pharmaceutical Biology.2014, 1

[10]

Interleukin-22 and rheumatoid arthritis: Emerging role in pathogenesis and therapy.[J].Qiang Xie;Cheng Huang;Jun Li.Autoimmunity.2014, 2

← 1 2 3 →